Cure8 research brief
This correction updates duplicated data points and clarifies methods in a preclinical synthetic-biology study about engineered materials that secrete therapeutic proteins for IBD, which affects interpretation and reproducibility for researchers.
Researchers in synthetic biology and IBD therapeutics; translational scientists and clinicians following novel biologic-delivery platforms.
This item is an author correction (erratum) to a research article in Nature Biotechnology that reported engineered "living glues"—synthetic biology constructs that secrete therapeutic proteins—for treatment of inflammatory bowel disease.
The correction fixes duplicated data points in figures and updates the statistical-analysis wording, some figure legends ("ex vivo" replacement), and associated source data, figures, and reporting summary. The corrected figures and original versions (for comparison) are available with the amendment.
This is an erratum (author correction) to a Nature Biotechnology paper; it replaces figures, source data and reporting details and does not introduce new clinical findings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Mitochondrial dysfunction may be a central contributor to UC inflammation and is being targeted by new therapeutic strategies that could lead to different treatment approaches in the future.
The study maps how two ginger preparations differently affect metabolism and the gut microbiome in a mouse model of ulcerative colitis, which could inform more targeted use of ginger-derived treatments if findings are...
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
